RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. GSK
G

GSK portfolio

GSK has 2 portfolio companies on record at Recent Funding, with 1 investment in the last 12 months.

Type: Investor.
Portfolio on Recent Funding: 2.
Deals, last 12 months: 1.
Capital in their rounds: $483M.
Latest deal: LifeMine Therapeutics · Aug 6, 2026.
About this page

Its most recent investment on record is LifeMine Therapeutics's $188M Series B+ round in August 2026, alongside Milky Way Investments, ARCH Venture Partners, Gates Frontier and 2 others. By category, its portfolio leans toward Health and bio (2). It has co-invested with ARCH Venture Partners, RA Capital Management and Bezos Expeditions, most often ARCH Venture Partners (2 rounds).

What GSK invests in

GSK recent investments

How GSK invests

StageDealsCapital in rounds
Series B+ 2 67%$363M
Series A 1 33%$120M
YearDealsCapital in rounds
2022 1 33%$175M
2025 1 33%$120M
2026 1 33%$188M

GSK portfolio companies

CompanyRound with GSKTotal raisedLatest raise
LLifeMine Therapeutics
Health and bio
Series B+ · $188M$543MAug 6, 2026
Series B+
OOuro Medicines
Health and bio
Series A · $120M$120MJan 10, 2025
Series A

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Share is of the 3 rounds on Recent Funding that name GSK. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists GSK, which is a subset of its real portfolio. API: /api/v1/investors/gsk (get a free API key). More: the most active VC firms and new venture capital funds.